Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Non-Current Debt for 6 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 50.74% to $49.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.4 million through Dec 2025, down 50.74% year-over-year, with the annual reading at $49.4 million for FY2025, 50.74% down from the prior year.
  • Non-Current Debt for Q4 2025 was $49.4 million at Lexicon Pharmaceuticals, down from $56.5 million in the prior quarter.
  • The five-year high for Non-Current Debt was $100.3 million in Q4 2024, with the low at $48.8 million in Q1 2023.
  • Average Non-Current Debt over 3 years is $80.5 million, with a median of $99.0 million recorded in 2023.
  • The sharpest move saw Non-Current Debt soared 104.47% in 2024, then crashed 50.74% in 2025.
  • Over 3 years, Non-Current Debt stood at $99.5 million in 2023, then grew by 0.79% to $100.3 million in 2024, then plummeted by 50.74% to $49.4 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $49.4 million, $56.5 million, and $56.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.